Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB
Lund, Sweden, October 31, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in prepa ...
Alligator Bioscience AB reports financial results for the first 9 months of 2024 and for Q3 2024 and provides a business update
Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...
Alligator Bioscience Apppoints Johan Giléus as Chief Financial Officer
Lund, Sweden, June 14, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Johan Giléus as ...
Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2024
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience AB reports financial results for Q1 2024 and provides a business update
Mitazalimab Phase 3 preparations underway following positive top-line results from OPTIMIZE-1 Phase 2 study in pancreatic cancer Positive in ...
Last day of trading in paid subscribed units (Sw. BTU) in Alligator
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator publishes outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Notice of annual general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...